Artax Biopharma Highlights AX-158 Advances at ACR Annual Meeting
In an exciting development for the field of biotechnology, Artax Biopharma, Inc. announced the acceptance of two abstracts for poster presentation during a renowned medical gathering. This event, held by the American College of Rheumatology, will shed light on groundbreaking research regarding AX-158, a first-in-class Nck modulator.
AX-158: A Promising Solution for Autoimmune Diseases
The mechanism of action for AX-158 demonstrates enormous potential to address a variety of autoimmune diseases without leading to immunosuppression. The Phase 1 data indicates that AX-158 was well tolerated among participants, which supports its advancement into further clinical studies.
Upcoming Presentations at ACR Convergence 2024
Artax Biopharma CEO, Rob Armstrong, expressed optimism as he stated, "We look forward to presenting on AX-158 and Nck modulation at ACR, welcoming the chance to engage with both the scientific and medical communities regarding our novel mechanism of action." The abstracts will be presented during a prestigious event taking place over several days in mid-November.
Details on Key Presentations
Among the significant presentations, one titled "TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases" will be led by Christopher VanDeusen, poster 1854, on November 18.
Another compelling presentation is titled "First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of the T cell Receptor Signal Modulator AX-158," presented by D Scott Batty, poster 1134, on November 17.
Phase 2a Trial of AX-158 in Psoriasis
AX-158 is currently being tested in a Phase 2a Proof-of-Mechanism study involving patients with mild to moderate plaque psoriasis across multiple centers. The trial has randomized participants to receive either AX-158 or a placebo over a period of 28 days, with an anticipated follow-up for an additional 30 days post-treatment to monitor safety.
The topline results for this study are expected to be reported later this year, allowing the company and stakeholders to assess the drug's efficacy and further potential in treating psoriasis.
Revolutionizing Autoimmune Disease Treatment
Artax Biopharma is committed to transforming the treatment landscape for T Cell-driven autoimmune diseases. Their innovative approach focuses on utilizing first-in-class oral small molecules designed to modulate immune responses without causing immunosuppression. This novel methodology is pivotal in unlocking new therapy options as both monotherapy and in combination with existing treatments.
AX-158's ability to deliver Phase 2a Proof of Concept data in psoriasis later this year marks a significant milestone for the company. The organization believes in the high potential of Nck modulation to revolutionize the treatment of T Cell-driven diseases by effectively maintaining control over immune system functions, thereby addressing the root causes of such conditions.
The strong broad cytokine modulation observed with AX-158, combined with encouraging data from various preclinical studies, suggests that the drug might have a significant impact on several autoimmune conditions. The absence of immunosuppression observed in models is particularly promising, indicating that AX-158 could provide safe and effective treatment alternatives.
About Artax Biopharma
Based in the Boston area, Artax Biopharma continues to lead the charge in addressing unmet medical needs within the autoimmune space. Backed by substantial funding through Series A & B investments from esteemed partnerships, the company encourages further exploration into their innovative research.
Artax Biopharma is dedicated to delivering therapies that not only treat but also enhance the overall function of the immune system. With the upcoming presentation of AX-158 and continued exploration of their therapies, the company remains poised for success in the biotechnology landscape.
Frequently Asked Questions
What is AX-158?
AX-158 is a first-in-class Nck modulator developed by Artax Biopharma, aiming to treat autoimmune diseases without causing immunosuppression.
When will the Phase 2 data for AX-158 in psoriasis be available?
The topline results from the Phase 2a trial for AX-158 in psoriasis are expected to be reported later this year.
What are the upcoming presentation dates for Artax Biopharma at ACR?
Artax Biopharma will present on AX-158 on November 17 and 18 during the ACR Annual Meeting.
Who is presenting the AX-158 research at ACR?
Research on AX-158 will be presented by company representatives, Rob Armstrong, Christopher VanDeusen, and D Scott Batty.
Where is Artax Biopharma based?
Artax Biopharma is headquartered in the Boston area and focuses on innovative solutions for T Cell-driven autoimmune diseases.
